Zealand Pharma A/S – American Depositary Shares (NASDAQ:ZEAL) Sellers Strengthened Their Shorts By 9.18%

June 29, 2018 - By Loretta Love

It was noted an increase on Zealand Pharma A/S – American Depositary Shares (NASDAQ:ZEAL)’s shorted shares with 9.18%. FINRA issued shorted shares of ZEAL’s total 254,500 shares. That’s 9.18% up from 233,100 shares. With Average volume 6,100, ZEAL’s previous position will take 42 days to recover. 1.1% is Zealand Pharma A/S – American Depositary Shares float short.

ZEAL is touching $13 during the last trading session, after increased 0.54%.Currently Zealand Pharma A/S is after 0.00% change in last June 29, 2017. ZEAL has 3,000 shares volume. The stock underperformed the S&P500 by 12.57%.

Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide therapeutics medicines in Denmark.The firm is worth $424.62 million. It has a portfolio of proprietary medicines in late-stage clinical development focusing on gastrointestinal and metabolic diseases.Currently it has negative earnings. The firm markets lixisenatide for the treatment of type 2 diabetes under the brand names of Adlyxin and Lyxumia; and a combination of lixisenatide and insulin glargine for the treatment of type 2 diabetes under the brand names of Soliqua 100/33 and Suliqua.

Another two news for Zealand Pharma A/S (NASDAQ:ZEAL) were briefly announced by: Seekingalpha.com on June 11, 2018 with title “Your Daily Pharma Scoop: Zealand Dips, Eloxx Surges, Venetoclax Approved”. The other Streetinsider.com‘s article was titled “Zealand Pharma (ZEAL) Phase 3 Trial of Dasiglucagon Met Primary and Secondary Objectives” and announced on June 08, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: